With the advent of genetic therapies, clinicians will also need to understand the varying levels of evidence for variants in known ALS‐associated genes such as SOD1 and be able to counsel patients on the likelihood of therapeutic success, taking into account all available evidence. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.